This is a status update on regulatory pathways with no new data — the stock is unlikely to move on this filing alone. Monitor for actual Phase III data readouts for Namodenoson (HCC) and Piclidenoson (psoriasis), which are the true catalysts. Given the $7M market cap and pre-revenue status, any clinical failure would be binary.
Price Chart
Executive Summary
Can-Fite BioPharma issued a press release on August 12, 2026, highlighting the advanced FDA and EMA regulatory status of its two lead Phase III drug candidates, Namodenoson and Piclidenoson. The filing is a routine regulatory update with no new clinical data or financial results, and the company's $7M market cap and history of losses indicate it remains a high-risk, pre-revenue clinical-stage biotech. The cross-filing context shows this is an annual update combined with activist and offering contexts, but the content itself is purely a status report on regulatory pathways, making the impact neutral.
Key Facts
- Namodenoson is in a pivotal Phase III study for advanced liver cancer (HCC) with Child-Pugh B7 cirrhosis under FDA and EMA guidance.
- Piclidenoson is in a Phase III program for moderate-to-severe plaque psoriasis.
- Namodenoson holds FDA Fast Track designation and FDA/EMA Orphan Drug designations.
- No new clinical data, financial results, or material agreements were disclosed in this filing.
Financial Impact
No financial figures reported in this filing. Company has a $7M market cap and a history of losses per the 20-F.
Risk Factors
- No new clinical data — regulatory status updates alone do not de-risk the pipeline.
- Company has a history of losses and needs additional capital to fund operations, per the 20-F risk factors.
- NYSE American continued listing requirements risk noted in the forward-looking statements.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-088029 |
| Document: ea030172601ex99-1.htm | 0001213900-26-088029 |
| Document: 0001213900-26-088029-index-headers.html | 0001213900-26-088029 |
| Document: 0001213900-26-088029-index.html | 0001213900-26-088029 |
| Document: 0001213900-26-088029.txt | 0001213900-26-088029 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 6-K | $1.95 | awaiting T+5 | — | $1.65 (−15.13%) |
Oct 13, 2026 14d ago | EFFECT | $1.95 $1.89 | ▲ +3.08% | ▲ +1.93% | $1.65 (+15.13%) |
Oct 13, 2026 14d ago | EFFECT | $1.95 $1.89 | ▲ +3.08% | ▲ +1.93% | $1.65 (+15.13%) |
Sep 14, 2026 6w ago | EFFECT | $2.30 $2.22 | ▲ +3.48% | ▲ +3.58% | $1.65 (+28.04%) |
Sep 9, 2026 6w ago | 6-K | $2.19 $2.24 | ▲ +2.28% | ▲ +3.38% | $1.65 (−24.43%) |
Sep 3, 2026 7w ago | 6-K | $2.35 $2.33 | ▼ −0.85% | ▲ +0.30% | $1.65 (−29.57%) |
Sep 2, 2026 7w ago | 6-K | $2.36 $2.16 | ▼ −8.47% | ▼ −7.52% | $1.65 (−29.87%) |
Sep 2, 2026 7w ago | Press Release | $2.36 $2.16 | ▲ +8.47% | ▲ +7.52% | $1.65 (+29.87%) |
Sep 2, 2026 7w ago | 6-K | $2.36 $2.16 | ▼ −8.47% | ▼ −7.52% | $1.65 (−29.87%) |
Aug 17, 2026 10w ago | 6-K | $3.58 $3.35 | ▼ −6.42% | ▼ −5.23% | $1.65 (−53.77%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers